Documentdetail
ID kaart

doi:10.1186/s12911-024-02484-5...

Auteur
Papaiz, Fabiano Dourado, Mario Emílio Teixeira, Jr. Medeiros Valentim, Ricardo Alexsandro Pinto, Rafael Morais, Antônio Higor Freire Arrais, Joel Perdiz
Langue
en
Editor

BioMed Central

Categorie

Medicine & Public Health

Jaar

2024

vermelding datum

20-03-2024

Trefwoorden
amyotrophic lateral sclerosis prognosis machine learning health informatics patients diagnosis algorithms
Metriek

Beschrijving

Prognosticating Amyotrophic Lateral Sclerosis (ALS) presents a formidable challenge due to patients exhibiting different onset sites, progression rates, and survival times.

In this study, we have developed and evaluated Machine Learning (ML) algorithms that integrate Ensemble and Imbalance Learning techniques to classify patients into Short and Non-Short survival groups based on data collected during diagnosis.

We aimed to identify individuals at high risk of mortality within 24 months of symptom onset through analysis of patient data commonly encountered in daily clinical practice.

Our Ensemble-Imbalance approach underwent evaluation employing six ML algorithms as base classifiers.

Remarkably, our results outperformed those of individual algorithms, achieving a Balanced Accuracy of 88% and a Sensitivity of 96%.

Additionally, we used the Shapley Additive Explanations framework to elucidate the decision-making process of the top-performing model, pinpointing the most important features and their correlations with the target prediction.

Furthermore, we presented helpful tools to visualize and compare patient similarities, offering valuable insights.

Confirming the obtained results, our approach could aid physicians in devising personalized treatment plans at the time of diagnosis or serve as an inclusion/exclusion criterion in clinical trials.

Papaiz, Fabiano,Dourado, Mario Emílio Teixeira, Jr.,Medeiros Valentim, Ricardo Alexsandro,Pinto, Rafael,Morais, Antônio Higor Freire,Arrais, Joel Perdiz, 2024, Ensemble-imbalance-based classification for amyotrophic lateral sclerosis prognostic prediction: identifying short-survival patients at diagnosis, BioMed Central

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw